During the past decade, Houston Methodist Research Institute conducted 81 clinical trials. In the 10-year time frame, 81 clinical trials started and 52 clinical trials were completed, i.e. on average, 64.2% percent of trials that started reached the finish line to date. In the past 5 years, 34 clinical trials started and 34 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Houston Methodist Research Institute" #1 sponsor was "The Methodist Hospital Research Institute" with 11 trials, followed by "Eli Lilly and Company" with 6 trials sponsored, "Abbott Medical Devices" with 5 trials sponsored, "United Therapeutics" with 5 trials sponsored and "Daiichi Sankyo, Inc." with 5 trials sponsored. Other sponsors include 94 different institutions and companies that sponsored additional 84 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Houston Methodist Research Institute" #1 collaborator was "AstraZeneca" with 3 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 3 trials as a collaborator, "The Methodist Hospital Research Institute" with 3 trials as a collaborator, "Bayer" with 2 trials as a collaborator and "Genentech, Inc." with 2 trials as a collaborator. Other collaborators include 34 different institutions and companies that were collaborators in the rest 43 trials.

According to Clinical.Site data, the most researched conditions in "Houston Methodist Research Institute" are "Breast Cancer" (6 trials), "Atrial Fibrillation" (5 trials), "Pulmonary Hypertension" (5 trials), "Paroxysmal Atrial Fibrillation" (4 trials) and "Pulmonary Arterial Hypertension" (4 trials). Many other conditions were trialed in "Houston Methodist Research Institute" in a lesser frequency.

Most popular intervention types in "Houston Methodist Research Institute" are "Drug" (68 trials), "Device" (36 trials), "Other" (14 trials), "Biological" (10 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (24 trials), "Gemcitabine" (3 trials), "Oral treprostinil" (3 trials), "placebo" (3 trials) and "AG-348" (2 trials). Other intervention names were less common.

The vast majority of trials in "Houston Methodist Research Institute" are 120 trials for "All" genders, 7 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Houston Methodist Research Institute". undefined are not yet recruiting, 15 are recruiting, 16 are Active, not recruiting, and 5 are Enrolling by invitation. In total, there were 65 completed trials in Houston Methodist Research Institute, 1 suspended trials, and 21 terminated clinical trials to date.

Out of the total trials that were conducted in Houston Methodist Research Institute, 11 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 31 trials that are defined as “Not Applicable".